Omalizumab in the treatment of asthma

    loading  Checking for direct PDF access through Ovid

Abstract

Omalizumab was introduced in 2003 and is the first asthma drug to target IgE, the allergic antibody that initiates the allergic cascade. Well-controlled studies and post-marketing clinical experience have shown it to be an effective and safe medication. Treatment guidelines now recommend omalizumab as an add-on option for patients with moderate-to-severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long-acting β-agonists. Despite initial concerns, there is no evidence of any association with malignancy at this time. In our opinion, omalizumab is well-tolerated and significantly improves pulmonary function, decreases clinical symptoms and improves the quality of life in patients with uncontrolled allergic asthma.

Related Topics

    loading  Loading Related Articles